These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24106408)

  • 1. Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.
    Zhao X; Deng B; Xu XY; Yang SJ; Zhang T; Song YJ; Liu XT; Wang YQ; Cai DY
    World J Gastroenterol; 2013 Sep; 19(36):6069-76. PubMed ID: 24106408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3.
    Zhao X; Li L; Li S; Liu J; Wang H; Lin Y; Cai D
    Eur J Pharmacol; 2022 Aug; 929():175115. PubMed ID: 35738453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
    Theodorakis NG; Wang YN; Korshunov VA; Maluccio MA; Skill NJ
    World J Gastroenterol; 2015 Apr; 21(14):4126-35. PubMed ID: 25892862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvianolic Acid B reducing portal hypertension depends on macrophages in isolated portal perfused rat livers with chronic hepatitis.
    Zhao X; Jia H; Yang S; Liu Y; Deng B; Xu X; Zhang T; Zhou H; Zu C; Yin H; Li T; Song Y; Wang Y; Li P; Zou Z; Cai D
    Evid Based Complement Alternat Med; 2012; 2012():786365. PubMed ID: 23118797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
    Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacodynamic model of portal hypertension in isolated perfused rat liver.
    Zhang T; Xu XY; Zhou H; Zhao X; Song M; Zhang TT; Yin H; Li T; Li PT; Cai DY
    World J Gastroenterol; 2012 Feb; 18(5):472-8. PubMed ID: 22346254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
    Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension.
    Sacerdoti D; Jiang H; Gaiani S; McGiff JC; Gatta A; Bolognesi M
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):72-5. PubMed ID: 21856435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.
    Xu J; Cao H; Liu H; Wu ZY
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):503-8. PubMed ID: 18842497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
    Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
    Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current concepts on the role of nitric oxide in portal hypertension.
    Hu LS; George J; Wang JH
    World J Gastroenterol; 2013 Mar; 19(11):1707-17. PubMed ID: 23555159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in vascular reactivity of mesenteric arterioles in portal hypertensive and non-portal hypertensive rats.
    Zhang B; Ji LH; Zhang CG; Zhao G; Wu ZY
    World J Gastroenterol; 2019 Oct; 25(39):5953-5960. PubMed ID: 31660032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation.
    Geerts AM; Vanheule E; Praet M; Van Vlierberghe H; De Vos M; Colle I
    Int J Exp Pathol; 2008 Aug; 89(4):251-63. PubMed ID: 18715470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
    World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.